Objective: In recent years, increasing studies found that pre-treatment red blood cell distribution width (RDW) could predict clinical outcomes in various cancers. However, the prognostic value of pre-treatment RDW in lung cancer was inconsistent. Therefore, we performed a meta-analysis to determine prognostic value of pre-treatment RDW in lung cancer.Methods: We performed a search in PubMed, The Cochrane Library, EMBASE (via OVID), Web of Science, CNKI, Wanfang, VIP, SinoMed databases, then we identified all records up to February 15, 2019. Outcomes of interest were overall survival (OS) and disease-free survival (DFS). Hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were calculated to assess the relevance of pre-treatment RDW to OS in lung cancer.Results: We included ten articles in total. Pooled results revealed that elevated pre-treatment RDW was significantly associated with poor OS (HR = 1.55, 95% CI: 1.26-1.92, p < 0.001) and DFS (HR = 1.53, 95% Cl: 1.15-2.05; p = 0.004) in lung cancer. Further subgroup analysis manifested that lung cancer patients with elevated pre-treatment RDW had worse prognosis.Conclusions: A higher value of pre-treatment RDW indicated worse survival of patients with lung cancer. RDW may serve as a reliable and economical marker for prediction of lung cancer prognosis.

中文翻译：

---

肺癌治疗前红细胞分布宽度的预后价值：一项荟萃分析。

目的：近年来，越来越多的研究发现，治疗前的红细胞分布宽度（RDW）可以预测各种癌症的临床结局。然而，治疗前RDW在肺癌中的预后价值不一致。因此，我们进行了荟萃分析，以确定治疗前RDW在肺癌中的预后价值。方法：我们在PubMed，Cochrane图书馆，EMBASE（通过OVID），Web of Science，CNKI，Wanfang，VIP，然后，我们通过SinoMed数据库确定了截至2019年2月15日的所有记录。关注的结果是总体生存期（OS）和无病生存期（DFS）。计算危险比（HRs）和相应的95％置信区间（95％CI），以评估RDW与肺癌OS的相关性。结果：总共包括10篇文章。汇总结果显示，升高的治疗前RDW与不良OS（HR = 1.55，95％CI：1.26-1.92，p <0.001）和DFS（HR = 1.53，95％Cl：1.15-2.05; p = 0.004）显着相关。 ）。进一步的亚组分析表明，治疗前RDW升高的肺癌患者的预后较差。结论：治疗前RDW的值较高表明肺癌患者的生存期较差。RDW可以作为预测肺癌预后的可靠且经济的指标。较高的RDW预处理值表明肺癌患者的生存期较差。RDW可以作为预测肺癌预后的可靠且经济的指标。较高的RDW预处理值表明肺癌患者的生存期较差。RDW可以作为预测肺癌预后的可靠且经济的指标。